Conference call on Interim Report

Author's Avatar
Oct 06, 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / October 6, 2023 / XVIVO Perfusion AB (STO:XVIVO, Financial)(LSE:0RKL, Financial)(FRA:3XV, Financial) Invitation to attend XVIVO's conference call regarding the presentation of the interim report July-September 2023. The presentation will be held in English.

Time: Tuesday, October 24 at 2.00 pm. CET

If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions.
https://ir.financialhearings.com/xvivo-q3-2023

If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally.
https://conference.financialhearings.com/teleconference/?id=5002129

Participants from XVIVO:
Christoffer Rosenblad, CEO
Kristoffer Nordström, CFO

The press release for XVIVO's interim report July-September 2023 will be released on October 24, 2023 at 7:30 am. CET.

Before the conference call, slides will be available at the company web page, https://www.xvivoperfusion.com/corporate/financial-presentations/earnings-calls/

October 6, 2023
Gothenburg
XVIVO Perfusion AB (publ)

For further information, please contact:

Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: [email protected]
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: [email protected]

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

Attachments

Conference call on Interim Report

SOURCE: XVIVO Perfusion AB



View source version on accesswire.com:
https://www.accesswire.com/790742/conference-call-on-interim-report

img.ashx?id=790742